The American Burn Association estimates that 1.1 million people suffer burns annually in the United States, with approximately 45,000 requiring hospitalization. Severe burns are life-threatening injuries that require immediate surgical intervention. Frequently, this involves temporary coverage of the wounds with cadaver skin or synthetic dressings to prevent infection and dehydration because there are no full-thickness skin substitutes commercially available for the treatment of burns. Permanent closure of the wound is generally accomplished through split thickness skin autografting after the wound bed is sufficiently stable so that it will accept the transplanted tissue. Although this regimen is the standard of care for severe burns, serious drawbacks to this approach include the limited availability of and potential for pathogen transmission from cadaver skin. Painful donor site wounds created during autograft surgery, coupled with scarring in many instances is also another serious drawback. Although the healing process of the burn wound progresses in a fashion like other wounds, there is a large interplay of systemic factors in this process.
Kerecis has an ongoing commitment to advancing management of burn care. This is in part achieved through our burn research program funded by the U.S. Department of Defense, with a large clinical trial and the pipeline. This trial will be looking critically at both the temporizing an autograph-sparing effect of Kerecis™ Omega3 GraftGuide.
Visit Kerecis™ Omega3 GraftGuide for more information about our product.
Not Healthcare Advice
This Site is not intended to provide diagnosis, treatment or medical advice. Products, services, information and other content provided on this Site, including information that may be provided on this Site directly or by linking to third-party websites, are provided for informational purposes only. Information on this Site should not be considered as a substitute for advice from a healthcare professional. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Kerecis does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the Kerecis product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any Kerecis product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Kerecis representative if you have questions about the availability of Kerecis products in your area.